@moSth8 spoke to #BoneUp about the effect of semaglutide on bone mass - does weight loss lead to reduced bone strength? What can we do to prevent it? @richie_abel
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 RCT
In adults with increased fracture risk, semaglutide once weekly did not increase bone formation based on bone formation marker P-PINP
https://t.co/NyCGsk1bqK
@moSth8
@frost_nielsen
I am happy to share our latest paper! In this randomised clinical trial, we investigated the skeletal effects of the GLP-1 receptor agonist semaglutide in women and men with increased fracture risk but without diabetes. @frost_nielsen @EfeOuh
https://t.co/63hU8GBIRq
Remember to sign up for our PhD course on metabolic bone diseases. Great speakers and mentors, industry session, and project development in the beautiful town of Odense. Join us! @DDEA_Denmark @frost_nielsen
This open-access publication is the result of combining great international collaborations with fantastic supervisors and some osteoclast genetic dust from The Bioinformaticians magic wand: https://t.co/m622SZqcPQ
@frost_nielsen @RauchLabSDU@caroline_gorvin@KentSoee @KMEBLab
➡️Join us for the next ISBM ECI webinar: Bone and emerging incretin-based treatments for T2D and obesity with Prof. Morten Frost, JAN 25. 🦴🏋️ @frost_nielsen Register here: https://t.co/uENBJJf11H
Our latest publication in @JBMRPlus reveals that fracture rates declined in Danish men with #T1D and #T2D, and in Danish women with #T2D. The decline may be attributable to improved #diabetes management.
#epidemiology#fractures#diabetes
https://t.co/tABBSvCWBa
Congratulations to Dr @RowanSHardy1 who has received a UoB award for excellence in postdoctoral supervision. Rowan said, "Thank you to the past and present fantastic students who nominated me for the postdoctoral supervision award". Well done Rowan! #postdoc @UoBMDSPostGrad